Navigation Links
Nasal polyps from analgesics
Date:3/10/2008

If a patient develops respiratory problems after taking analgesics, this indicates that the active substances are poorly tolerated. This is pointed out by Prof. Hanns-Wolf Baenkler, Erlangen University Medical School, in the current edition of the Deutsches rzteblatt International (Dtsch Arztebl Int 2008; 105(8): 13742). One should also think of analgesic intolerance when patients suffer from chronic irritation of the gastrointestinal tract, without any recognizable allergy or infection.

Patients with these symptoms exhibit enhanced sensitivity and changes in the pattern of the so-called eicosanoids - important mediators of pain and inflammation. This change in pattern explains the specific reaction to salicylates and related COX inhibitors in analgesics, cosmetics, and vegetable foods. The classical symptoms of intolerance are rhinitis, bronchial asthma or nasal polyps, accompanied by inflammatory reactions in the intestine or skin and urticaria.

The diagnosis is based on symptoms immediately after taking salicylates or on recurrent polyp formation. Blood tests can be an important diagnostic aid, particularly in difficult cases. Discontinuation of treatment helps, as does corticosteroid treatment. Biological treatment is also possible, based on adaptation by administering increasing doses of acetylsalicylic acid.


'/>"/>

Contact: Dr. Stephan Mertens
stephan.mertens@aerzteblatt.de
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related medicine news :

1. Saline Nasal Wash Helps Kids Fight Colds, Flu
2. Protein Nasal Spray Revives Sleep-Deprived Monkeys
3. Saline Irrigation Eases Chronic Nasal Symptoms
4. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
5. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
6. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
7. Nosefrida Nasal Aspirator - A Parents Alternative to Medicines on the Verge of FDA Ban
8. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
9. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
10. Nasal Anthrax Vaccine Proves Effective in Animal Study
11. Smoking can double risk of colorectal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA Agency ... (AOR) for Theravent, Inc. , the makers of a revolutionary new device ... Healthcare, is now working to expand distribution in anticipation of a national launch. ...
(Date:4/21/2017)... ... 21, 2017 , ... Airway Management, the medical device manufacturer ... regarded and well renowned Asian distributor, Discovery Sleep. The agreement involves ... Mask, and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical ...
(Date:4/21/2017)... ... 21, 2017 , ... BrightStar Care Salt Lake City, a home care agency ... (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. “This ... and our ability to provide quality care to the community,” said Tammara Brown, owner ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, controversy, questions ... the Obamacare program that most Republicans love to hate and Texas Agriculture Commissioner ... hogs. , Like Obamacare, the Miller program centers upon a federal mandate. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: